Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNexus Gene LabBGLC 56 3-Year EBITDA Growth Rate is -126.90% as of Jun. 2026. GuruFocus rates BGLC with a GF Score™ of 56/100 and a GF Value™ of $1.24 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,408 Chemicals companies, BioNexus Gene Lab ranks worse than 99.93% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was -126.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of BioNexus Gene Lab was 90.50% per year. The lowest was -126.90% per year. And the median was 20.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
BioNexus Gene Lab 3-Year EBITDA Growth Rate Related Terms
BGLC vs CNEY, SNES, QGAI: 3-Year EBITDA Growth Rate Comparison
For the Specialty Chemicals subindustry, BioNexus Gene Lab's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab 3-Year EBITDA Growth Rate vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -126.90% mean?
BioNexus Gene Lab (BGLC) has a 3-Year EBITDA Growth Rate of -126.90% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for BioNexus Gene Lab and its competitors. According to the industry distribution chart, BioNexus Gene Lab ranks #1407 out of 1408 companies in the Chemicals industry, placing it in the top 99.9%.
Is BioNexus Gene Lab's 3-Year EBITDA Growth Rate too high?
BioNexus Gene Lab's current 3-Year EBITDA Growth Rate is -126.90%. Based on the distribution chart, BioNexus Gene Lab ranks #1407 out of 1408 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, BioNexus Gene Lab has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's 3-Year EBITDA Growth Rate compare to CNEY and SNES?
According to the Chemicals industry distribution chart, BioNexus Gene Lab ranks #1407 out of 1408 companies for 3-Year EBITDA Growth Rate. This places BioNexus Gene Lab in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 0.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Chemicals company?
The median 3-Year EBITDA Growth Rate among Chemicals companies is 0.80, based on 1,408 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for BioNexus Gene Lab and its competitors. For the Chemicals industry, the median 3-Year EBITDA Growth Rate is 0.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNexus Gene Lab's current 3-Year EBITDA Growth Rate is -126.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.24, compared to a current price of $1.47 — trading 18.5% above its estimated fair value. The current 3-Year EBITDA Growth Rate is -126.90%. BioNexus Gene Lab's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current 3-Year EBITDA Growth Rate is -126.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNexus Gene Lab (BGLC) Overvalued in 2026?
Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be overvalued.
The current stock price of $1.47 is trading 18.5% above its estimated GF Value™ of $1.24.
GuruFocus considers BioNexus Gene Lab to be Modestly Overvalued.
Key valuation signals for BGLC:
3-Year EBITDA Growth Rate: -126.90%
GF Value™: $1.24 vs. price of $1.47 (18.5% above fair value)
No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
56GF Score
Get the complete analysis for BGLC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLC has been successfully added to your 
